Diabetes drug switch: could a new combo improve blood sugar?
NCT ID NCT06972732
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether switching from one diabetes medication (DPP-4 inhibitor) to another (TZD) can better control blood sugar in people with type 2 diabetes who are already taking metformin and an SGLT2 inhibitor. About 204 adults will be randomly assigned to either stay on their current medication or switch to the new combination. The main goal is to see how much HbA1c (a measure of blood sugar control) changes after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin/Pioglitazone (a combination of two drugs: dapagliflozin and pioglitazone)
What this could lead to
If successful, this could show that switching to a TZD (pioglitazone) provides better blood sugar control than staying on a DPP-4 inhibitor for people with type 2 diabetes already taking metformin and an SGLT2 inhibitor.
What could go wrong
This is a relatively small, early-stage (Phase 4) trial with only 204 participants. Results may not apply to everyone with type 2 diabetes, and the new combination may cause side effects like weight gain or fluid retention.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Catholic University of Korea, Seoul St. Mary's Hospital
RECRUITINGSeoul, Seocho District, 06591, South Korea